The prognosis for patients with acute myeloid leukemia in first relapse is generally poor. The ability to induce a second complete remission (CR) with the same chemotherapy used in initial induction therapy is limited. Remission inversion rate, defined as achieving a longer second CR than the first CR in response to standard chemotherapy for relapse, is important in assessing studies of novel chemotherapy or immunologic treatment strategies for patients with relapsed disease. One hundred and twenty-four patients entered on two Eastern Cooperative Oncology Group (ECOG) studies for patients with relapsed AML were analyzed to determine the remission inversion rate. Twenty-two of the 124 patients (18%; 95% confidence interval 12-26%) experienced a longer second CR duration than the first CR duration by at least 2 months. Inversion of CR duration is thus not a rare event. The inversion frequency reported here establishes a baseline upon which future studies in relapsed disease need to be defined. Leukemia (2000) 14, 1345-1348.
Introduction
The majority of patients with newly diagnosed acute myeloid leukemia (AML) achieve complete remission (CR) with contemporary induction chemotherapy, which includes an anthracycline and cytosine arabinoside. [1] [2] [3] [4] [5] However, despite intensive consolidation chemotherapy, the majority of patients relapse and only approximately 20-40% of these patients remain in a durable CR. [6] [7] [8] [9] The ability to induce a second CR with the same chemotherapy that was used in induction therapy for patients with relapsed AML is limited. Only 25-40% of patients achieve a second CR and the median survival is generally less than 6 months. 10 Despite more intensive salvage regimens including newer agents, the median survivals remain short. 11, 12 The poor prognosis of these patients may be related to the level of expression of the multidrug resistance gene-1. 13 One important variable predicting the outcome of re-induction chemotherapy is the duration of the first CR. [14] [15] [16] [17] [18] In general, patients whose first CR is longer than 2 years have the potential for prolonged second CR with chemotherapy. 19, 20 The main purpose of this analysis was to assess the rate of remission inversion, that is, the incidence of a longer duration of the second CR than the first CR in patients with relapsed AML. To our knowledge, the only reported data in the literature noted an inversion rate of 28% in patients who were treated with timed sequential chemotherapy consisting of etoposide, mitoxantrone and cytosine arabinoside. 11 The esti-mate reported here was derived from the historical database of the ECOG.
Patients and methods

Studies included in the analysis
In order to compare the duration of the first and second CRs, data from two ECOG studies EST 5483 and 1487 were used. EST 5483 was a phase III study for patients with relapsed or refractory AML in which patients were initially treated with combination chemotherapy including high-dose cytarabine plus m-Amsacrine (m-AMSA), and those who achieved CR were subsequently randomized to either maintenance therapy with low-dose cytarabine or observation. 21 EST 1487 was a phase II study of mitoxantrone and etoposide in patients with relapsed and refractory AML. 22 After second CR, no treatment was administered. In these studies, a subset of patients who had only one CR prior to the study entry and then achieved second CR on study was included in the present analysis. Patients on E5483 or E1487 received no postremission therapy other than as prescribed.
Duration of CR
In calculating the first CR duration, the ECOG database provided information on a number of induction therapies and dates of initial diagnosis and recurrence, but did not contain data on the precise date when the previous CR was achieved. Thus, the duration of the first CR was estimated in the following manner. For the patients with one induction therapy, it was assumed that CR was achieved 1 month after the initial diagnosis, and for those who had multiple induction therapies, it was assumed that CR was achieved 2 months after the initial diagnosis. The duration of the second CR was measured from the date of the second CR to relapse for those who had relapsed or last known to be alive for those who remained leukemia-free. The inversion was defined for this study as a duration of second CR greater than the duration of the first CR by at least 2 months.
Statistical methods
To summarize the data, descriptive statistics such as median, range, confidence intervals and frequency tables were presented. For the estimated inversion rate, 95% confidence intervals were calculated using the exact binomial formula. The overall survival distributions were estimated according to the methods of Kaplan and Meier 23 and 95% confidence intervals were calculated using the Greenwood's method. 24 A median follow-up time for the survival time was estimated as the median of the censoring times. Univariate differences between categorical variables were evaluated using the Fisher's exact test. 25 (All P values reported are based on two-sided significance tests.)
Results
Patient population
In EST 5483, 111 patients were eligible for this inversion rate study. Among the patients achieving CR, 37 patients did not go on to the maintenance therapy, 37 were randomized to the observation arm and 37 to the maintenance Ara-C arm. In EST 1487, there were 20 eligible patients. However, seven patients (four on E5483 and three on E1487) had censored second CR duration and the second CR duration could not be compared to the first CR duration. Therefore, the analysis is based on 124 patients. Table 1 summarizes patient characteristics at study entry. By inspecting the first two columns of Table 1 , it appears that the patients in EST 5483 and EST 1487 had similar characteristics with respect to age, gender, race, ECOG performance status (PS) and French-American-British (FAB) cytologic and cytochemical type. The median age of all 124 eligible patients was 45 years (range 18-70 years). There were 60 males and 64 females. Eighty-five percent of the patients had white ethnic background. Fifty-two percent of the patients Table 1 On-study patient characteristics (n = 124) had PS 0 and 40% had PS 1. The most common FAB types were M1 and M2 which constituted 24% and 28% of the cases, respectively.
Inversion
Among the 124 eligible patients, 73 had a shorter second CR duration than the first CR duration by at least 2 months, 29 had a second CR duration within 2 months of the first CR duration and 22 had a longer second CR duration than the first CR duration by at least 2 months. Thus by the definition of the inversion given earlier, the estimated inversion rate is 17.7% (22/124) with a 95% confidence interval (11.5%, 25.6%). Table 2 presents patient characteristics by the inversion status. Nobody with performance status у2 had a greater second CR duration than the first CR duration by at least 2 months (P values = 0.11 by Fisher's exact test). The most common FAB types were and M1 (27.4%) and M2 (28.8%) among the patients with a shorter second CR duration and were M2 (22.7%) and M4 (27.3%) among the patients with a longer second CR duration. The distributions of FAB types between these two groups appear to be marginally different (P value = 0.07 by Fisher's exact test). Table 3 summarizes the CR durations by the inversion status. For the 22 patients with an inversion, the median difference in CR duration was 31.4 months (range 2.2-122.5 months). Table 2 On-study characteristics by inversion status (n = 124) 
Survival
The overall survival time distributions were similar in EST 5483 and EST 1487. For EST 5483, after a median follow-up of 10.9 years, 96 deaths were observed among 107 eligible patients. Ninety-five percent confidence interval for the estimated overall failure rate, 0.90 is (0.82, 0.95). A median follow-up time for the survival time was estimated as the median of the censoring times. The median survival time measured from randomization to the time of death or last known to be alive (censored) was 8.4 months, with a 95% confidence interval (7.3, 11.1). For EST 1487, after a median follow-up of 8.5 years, 14 deaths were observed among 17 eligible patients. Ninety-five percent confidence interval for the overall failure, 0.82 is (0.57, 0.96). The median survival time was 8.6 months, with a 95% confidence interval (6.4, 25.2).
Leukemia
Discussion
Although progress has been made in the treatment of patients with AML, relapse from an initial CR remains a frequent occurrence. New drugs either alone, or in combination, for recurrent leukemia are constantly being evaluated. Novel strategies including the use of immunotherapy and biologic response modifiers, are being used in an attempt to improve the therapy of patients with relapsed AML. An inversion rate of a second CR that is longer than the first CR has been used as a demonstration of the efficacy of new therapy. [26] [27] [28] Therefore, establishing the remission inversion rate from conventional therapy for relapse is an important benchmark. It allows one to evaluate induction therapy in relapsed or refractory AML and the use of post-remission immunologic treatment strategies. 29, 30 In the present analysis, 18% of patients with recurrent or refractory AML experienced a longer second CR duration than the first. Furthermore, maintenance therapy with low-dose Ara-C did not affect the inversion rate although such treatment prolonged the duration of second remission compared to observation. 21 Two-year survival rate in 124 patients was 21.4% with 95% confidence interval of (14.1%, 28.6%).
Despite a large number of published salvage regimens, remission inversion rates have been rarely addressed. For some time it was assumed that the occurrence of a longer second than the first complete remission was a rare event. This analysis demonstrates that an inversion of CR duration in not common, but is not rare. The results here are similar to those reported by Archimbaud and colleagues. 11 The only prognostic factor consistently shown to influence the duration of the second remission is the duration of first CR. In fact, among 806 patients in first relapse treated with a variety of salvage regimens, only those patients with a first CR of at least 2 years had any possibility for long-term survival. 19 This study estab-lishes a baseline to which future studies need to be compared. To demonstrate improved efficacy of an experimental regimen, it seems reasonable to suggest that an inversion rate of at least 30% should be demonstrated before such a regimen should be studied in a phase III fashion.
